Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAGM.L Regulatory News (AGM)

  • There is currently no data for AGM

Board Changes

29 Jun 2018 10:19

RNS Number : 0590T
Applied Graphene Materials PLC
29 June 2018
 

 

 

29th June 2018

 

Applied Graphene Materials plc

 

("Applied Graphene Materials", "the Group", "the Company" or "AGM")

 

Board Changes

 

Applied Graphene Materials, the producer of specialty graphene materials, is pleased to announce that it intends to appoint Dr. Hugh Adrian Potts (Adrian), aged 57, to the Board as the Group's new Chief Executive Officer, following the announcement earlier in the year of the retirement of current CEO Jon Mabbitt.

 

Adrian has been Vice President for Business Development at AGM since January 2015. In this role he was responsible for leading the company's business development strategy in the U.S. Adrian previously worked at Cytec Process Materials in roles including Global Business Development Director, President of Cytec Process Materials, CA Inc. and President of Umeco Structural Materials Inc.

 

In addition, the Board announces that Gareth Jones, Chief Financial Officer, has given notice of his resignation. The Board's recruitment process to appoint a successor will commence immediately and an announcement will follow in due course. Gareth will remain with the Company beyond the announcement of AGM's annual results to ensure a smooth handover to his successor.

 

Dr. Bryan Dobson, Non-Executive Chairman of AGM, commented:

 

"We are delighted that Adrian has agreed to take on the role of CEO. He already has an in-depth understanding of AGM's unique offer and strategy and has the skills to take the Group to the next level. On behalf of the Board, I would like to thank Gareth Jones for his contribution during his time at AGM and wish him all the best in his future career."

 

A further announcement will be made on commencement of Adrian Pott's appointment setting out the additional required disclosures pursuant to Rule 17 and Schedule 2 (g) of the AIM Rules for Companies.

 

Ends

 

 

For further information, please contact:

 

N+1 Singer +44 (0) 207 496 3000

Richard Lindley / James White

 

Hudson Sandler +44 (0) 207 796 4133

Charlie Jack / Emily Dillon

Notes to Editors

Applied Graphene Materials was founded by Professor Karl Coleman in 2010 with its operations and processes based on technology that he initially developed at Durham University. The Group is based at the Wilton Site on Teesside and was admitted to AIM in November 2013.

The Group has developed proprietary bottom-up processes which are capable of producing high purity graphene nanoplatelets using a continuous process. The manufacturing processes are based on sustainable, readily available raw materials and therefore do not rely on the supply of graphite, unlike a number of other graphene production techniques. Applied Graphene Materials owns the intellectual property and know-how behind these processes.

Applied Graphene Materials works in partnership with its customers using its knowledge and expertise to provide bespoke graphene dispersions and formats to deliver enhancements and benefits for a wide range of applications.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
BOAEANKNAFPPEEF
Date   Source Headline
11th Jan 20163:36 pmRNSDirector/PDMR Shareholding
8th Jan 201612:13 pmRNSResult of Meeting
18th Dec 20157:00 amRNSPlacing and Open Offer
16th Nov 20157:00 amRNSFull Year Results
23rd Oct 20157:00 amRNSJoint Development Agreements and Collaborations
21st Sep 20155:19 pmRNSHolding(s) in Company
18th Sep 20157:00 amRNSPeriod end trading update
9th Jul 20157:00 amRNSIssue of share options to Directors
30th Jun 20153:36 pmRNSHolding(s) in Company
17th Jun 20157:00 amRNSFirst Patent Approval
19th May 20154:40 pmRNSSecond Price Monitoring Extn
19th May 20154:35 pmRNSPrice Monitoring Extension
14th May 20157:00 amRNSPositive results from independent oil trials
27th Apr 20159:21 amRNSHolding(s) in Company
22nd Apr 20154:44 pmRNSHolding(s) in Company
22nd Apr 20153:28 pmRNSHolding(s) in Company
21st Apr 20154:46 pmRNSHolding(s) in Company
17th Apr 20157:00 amRNSPositive results from independent coatings trials
2nd Apr 20159:46 amRNSHolding(s) in Company
1st Apr 20154:39 pmRNSHolding(s) in Company
25th Mar 20157:00 amRNSInterim Results
3rd Feb 20157:00 amRNSTrading Update
27th Jan 201511:25 amRNSIssue of equity and total voting rights
22nd Jan 20157:00 amRNSSenior Management Appointments
22nd Dec 20147:00 amRNSDirectorate Change
15th Dec 201411:36 amRNSResult of AGM
15th Dec 20147:00 amRNSAGM Statement
24th Nov 20147:00 amRNSPosting of Annual Report and Notice of AGM
17th Nov 20147:00 amRNSInvestor site visit
5th Nov 20147:00 amRNSAppointment of Non-Executive Director
5th Nov 20147:00 amRNSFull Year Results
5th Sep 20147:00 amRNSPre-close update
28th Jul 20147:00 amRNSIssue of share options to Directors
9th Jul 201410:17 amRNSGrant of Options to Directors
2nd Jul 20144:36 pmRNSHolding(s) in Company
23rd May 20143:08 pmRNSIssue of Share Options
30th Apr 20143:40 pmRNSReplacement - Holding(s) in Company
28th Apr 20148:50 amRNSHolding(s) in Company
1st Apr 20147:00 amRNSAppointment of Non Executive Director
1st Apr 20147:00 amRNSInterim Results
19th Mar 20147:00 amRNSNotice of Interim Results
18th Mar 201411:00 amRNSDirectorate Change
20th Jan 20144:39 pmRNSHolding(s) in Company
15th Jan 201410:59 amRNSIssue of Equity
27th Nov 20134:40 pmRNSSecond Price Monitoring Extn
27th Nov 20134:35 pmRNSPrice Monitoring Extension
26th Nov 20134:40 pmRNSSecond Price Monitoring Extn
26th Nov 20134:35 pmRNSPrice Monitoring Extension
22nd Nov 201312:39 pmRNSHolding(s) in Company
20th Nov 20137:00 amRNSAdmission and First Day of Dealings on AIM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.